Skip to search formSkip to main contentSkip to account menu

ECOG Performance Status 1

Known as: ECOG 1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Concurrent chemoradiotherapy for head and neck cancers in older patients: Outcomes and their determinants
INTRODUCTION: Meta-analyses have shown concurrent chemoradiotherapy (CCRT) provides no survival benefit over radiotherapy in… 
2018
2018
Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
618Background: Tivozanib is a VEGFR-TKI with high specificity and lower incidence of class effect adverse events. As combinations… 
Review
2016
Review
2016
DI-003 Paclitaxel-carboplatin induced peripheral neuropathy in ovarian cancer patients
Background Administration of paclitaxel is associated with an increased survival rate in ovarian cancer patients. Despite the… 
2013
2013
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
2012
2012
A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.
2552 Background: Eribulin mesylate is a microtubule dynamics inhibitor approved by FDA for patients (pts) with metastatic breast… 
2012
2012
Physical function and quality of life in frail and/or elderly metastatic colorectal cancer patients treated with bevacizumab and capecitabine: An exploratory analysis.
627 Background: Optimal treatment strategies in frail and/or elderly patients with metastatic colorectal cancer have not been… 
2011
2011
MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report.
4501 Background: "Intracrine" androgen signaling is linked to castrate-resistant prostate cancer (CRPC) and a "credentialed… 
2009
2009
Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto).
5048 Background: AA is a potent blocker of CYP17, required for synthesis of testosterone in the testes, adrenals, and prostate… 
2004
2004
Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial…
2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor… 
2002
2002
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer.
PURPOSE The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)